Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-03
2005-05-03
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S256000, C514S269000, C544S238000, C544S242000, C544S295000, C544S296000, C544S319000, C544S322000, C544S333000, C544S334000, C544S335000
Reexamination Certificate
active
06887875
ABSTRACT:
Diarylpyrimidine compounds of Formula I are provided, wherein.or a pharmaceutically acceptable salt thereof, wherein:Ar1and Ar2are independently chosen from:phenyl which is mono-, di-, or tri-substituted,1-naphthyl and 2-naphthyl, each of which is optionally mono-, di-, or tri-substituted, andoptionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one of said rings, from 1 to about 3 heteroatoms selected from the group consisting of N, O, and S;R is oxygen or absent;Z2is CR2; Z3is nitrogen;R1and R2are independently chosen from hydrogen, halogen, amino, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted mono- or di-alkylamino, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (cycloalkyl)oxy, optionally substituted (cycloalkyl)alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted mono- or dialkylcarboxamide; with the proviso that not all of R1, R3, and R4are hydrogen.These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatments of such disorders and well as packaged pharmaceutical compositions are also provided.Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
REFERENCES:
patent: 3660404 (1972-05-01), Otterstedt et al.
patent: 4788197 (1988-11-01), Wakabayashi et al.
patent: 6107297 (2000-08-01), Kindon et al.
patent: 6686469 (2004-02-01), Eberle et al.
patent: 2318368 (1999-08-01), None
patent: 2-243676 (1990-09-01), None
patent: WO 2000066565 (2000-11-01), None
Zobel J. Psych. Res., vol. 34, 2000, 171-181.*
McCarthy, J.R. et al, Ann. Reports Med. Chem., vol. 34, pp. 11-20, 1999.*
N. Vinot et al., “Synthese de pyrazines,” Bulletin De La Societe Chimque De France, No. 12, (1968) pp. 4970-4974.
V. Baliah & K. Pandiarajan, “Synthesis of Some 2,3-Dihydropyrazines, Pyrazines & Piperzines,” Dept. of Chem., Annamalai University, Ammamalainagar 608101, pp. 73-75.
G. Alvernhe et al., Tetrahedron letters, vol. 21, Pergamon Press Ltd (1980), pp-1437-1440.
J. Chellappa et al., “PMR Sprectra of Some Substituted Pyrazines & 2,3-Dihyropyrazines,” Indian Journal of Chemistry, vol. 21B, Aug. 1982, pp. 778-779.
Y. Akita et al., “Cross-coupling Reaction of Chloropyrazines with Acetylenes,” Chem. Phar, Bull., vol. 43, No. 4, Aug. 1985, pp. 1447-1458.
A. Ohta et al., “Coupling Reaction of Chloropyrazines and Their N-Oxides with Tetraphenyltin,” Heterocycles, vol. 24, No. 3, 1986, pp. 785-792.
T. Benincori et al., “Studies on the Fischer Indole Synthesis: Rearrangements of Five-, Six- and Seven-membraned Cylic Hydrazones of Pyrazoline, Tetrahydropyridazine and Tetrahydro-1,2-diazepine Series in Polyphosphoric Acid,” J. Chem. Soc. Perkin Trans., 1991, pp. 2139-2125.
A. Ohta et al., “Anti-Platelet Aggregation Activity of Some Pyrazines,” Biol. Pharm. Bull. vol. 20, No. 10, 1997, pp. 1076-1081.
C. Yamagami et al., “Measurement and Production of Hydrophobicity Parameters for Highly Lipophilic Compounds: Application of the HPLC Column-Switching Technique to Measurement of log P of Diarylpyrazines,” Journal of Pharm. Sciences, vol. 88, No. 12, 1999, pp-1299-1303.
On-lie Database Search identifying CAPLUS and MEDLINE using the phrase “diarylpyrazine,” 2001.
On-lie Database Search identifying CAPLUS and MEDLINE using the phrase “arylpyrazines,” 2001.
Doller Dario
Ge Ping
Hodggetts Kevin
Huang Jianhua
Yamaguchi Yasuchika
Alexander John B.
Corless Peter F.
Edwards & Angell LLP
McKenzie Thomas C.
Neurogen Corporation
LandOfFree
2,5-diarypyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,5-diarypyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,5-diarypyrimidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3419564